Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today. Ms. Dorton has more than 30 years of industry expertise and leadership in healthcare and life sciences including service on several boards of public life science companies, executive financial leadership and investment banking.

Read more at globenewswire.com